Citations

Clear

815 citation(s) found for "Tang, Yu".

NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-po
Tang, Gong , Rastogi, Priya , Atkins, James N., Donnellan, Paul , Azar, Catherine A., Robidoux, André, Polikoff, Jonathan, Biggs, David D., Zapas, John L., Provencher, Louise , Perez, Edith A. , Costantino, Joseph P., Mamounas, Eleftherios P. , Swain, Sandra M. , Geyer, Charles E. , Fehrenbacher, Louis , Brufsky, Adam , Levine, Edward A. , Paik, Soonmyung , Mamounas, Eleftherios P. , Wolmark, Norman

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: LBA1000-LBA1000

10.1200/jco.2012.30.15_suppl.lba1000 Get It

LBA1000 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease
Tang, W.H. Wilson , Wilcox, Jennifer , Jacob, Miriam , Frantz, Robert P. , Hill, Nicholas S. , Singh, Harsimran , Xiao, Lei , Rischard, Franz , Group, the PVDOMICS Study, Tang, W H Wilson , Frantz, Robert P , Rischard, Franz P , Wilcox, Jennifer D , Rosenzweig, Erika B. , Borlaug, Barry A. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Systrom, David M , Tedford, Ryan J. , Vanderpool, Rebecca , Waxman, Aaron B. , Leopold, Jane A. , Group, the PVDOMICS Study

Mayo Clinic

Circulation: Heart Failure | February 24, 2020 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/circheartfailure.119.006363 | PMID 32088984 Get It

Background: Invasive hemodynamic evaluation through right heart catheterization plays an essential role in the diagnosis, categorization, and risk stratification of patients with pulmonary hypertension. Methods: Subjects enrolled in the PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) program undergo an extensive invasive hemodynamic evaluation that includes repeated measurements at rest and during several provocative physiological challenges. It is a National Institutes of Health/National Heart, Lung, and Blood Institute initiative to reclassify pulmonary hypertension groups based on clustered phenotypic and phenomic characteristics. At a subset of centers, participants also undergo an invasive cardiopulmonary exercise test to assess changes in hemodynamics and gas exchange during exercise. Conclusions: When coupled with other physiological testing and blood -omic analyses involved in the PVDOMICS study, the comprehensive right heart catheterization protocol described here holds promise to clarify the diagnosis and clustering of pulmonary hypertension patients into cohorts beyond the traditional 5 World Symposium on Pulmonary Hypertension groups. This article will describe the methods applied for invasive hemodynamic characterization in the PVDOMICS program. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02980887.
Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)
Smoragiewicz, Martin , Adjei, Alex A. , Calvo, Emiliano , Tabernero, Josep , Marabelle, Aurélien , Massard, Christophe , Vries, Elisabeth G.E. de , Douillard, Jean-Yves , de Vries, Elisabeth G E , Douillard, Jean-Yves , Tabernero, Josep , Calvo, Emiliano , Tang, Jun , Seymour, Lesley

Mayo Clinic

Clinical Cancer Research | February 21, 2020 | Volume: 26 | Issue: 11 | Pages: 2461-2465

10.1158/1078-0432.ccr-19-3136 | PMID 32086344 Get It

Abstract Purpose: To review key aspects of the design and conduct of early clinical trials (ECT) of immunotherapy agents. Experimental Design: The Methodology for the Development of Innovative Cancer Therapies Task Force 2019 included experts from academia, nonprofit organizations, industry, and regulatory agencies. The review focus was on methodology for ECTs testing immune-oncology therapies (IO) used in combination with other IO or chemotherapy. Results: Although early successes have been seen, the landscape continues to be very dynamic, and there are ongoing concerns regarding the capacity to test all new drugs and combinations in clinical trials. Conclusions: Optimization of drug development methodology is required, taking into account early, late, and lower grade intolerable toxicities, novel response patterns, as well as pharmacodynamic data.
Systematic use of fluorescence in‐situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms
Fang, Hong , Loghavi, Sanam , Greipp, Patricia T. , Wang, Wei , Verstovšek, Srđan , Reichard, Kaaren K. , Miranda, Roberto N. , Wang, Sa A. , Loghavi, Sanam , Greipp, Patricia, Wang, Wei , Verstovsek, Srdan , Greipp, Patricia T , Miranda, Roberto N , Tang, Guilin , Medeiros, L. Jeffrey

Mayo Clinic

Histopathology | February 21, 2020 | Volume: 76 | Issue: 7 | Pages: 1042-1054

10.1111/his.14097 | PMID 32083752 Get It

AimsRearrangement of the platelet‐derived growth factor receptor B (PDGFRB) gene defines a unique group of myeloid/lymphoid neoplasms with frequent eosinophilia and high sensitivity to tyrosine kinase inhibitors. This genetic abnormality is also rarely reported in Philadelphia‐like B‐cell acute lymphoblastic leukaemia/lymphoma (B‐ALL). PDGFRB rearrangement was initially thought to only occur in cases with 5q31–33 rearrangement as determined with conventional cytogenetics; however, there are reported cases with cryptic rearrangements. We aim to develop a broader strategy for screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms.Methods and resultsWe performed fluorescence in‐situ hybridisation (FISH) for PDGFRB rearrangement in 197 patients, including 70 with B‐ALL, 10 with myeloid neoplasms with 5q31–33 rearrangements, and 117 with eosinophilia (≥0.5 × 109/l in peripheral blood or ≥5% in bone marrow), and identified PDGFRB rearrangement in four of 197 (2.0%) cases. In an attempt to identify clinicopathological and genetic features that may have a stronger association with PDGFRB rearrangement, we analysed 13 patients with confirmed PDGFRB rearrangements, including 10 with myeloid neoplasms and three with B‐ALL. Among the 10 patients with myeloid neoplasms, eosinophilia was present in eight, monocytosis in two, 5q31–33 rearrangement in seven, and abnormal bone marrow morphology in all. All patients with myeloid neoplasms showed an excellent response to imatinib, including a patient in blast crisis. The three B‐ALL patients presented de novo, showed no eosinophilia, had a complex karyotype including 5q31–33 rearrangement, and had clinically aggressive courses with ultimate patient demise.ConclusionsThese findings suggest that a higher yield for the identification of PDGFRB rearrangement may result from an index of suspicion in patients with eosinophilia, monocytosis, bone marrow features of a myeloid neoplasm, and 5q31–33 rearrangement, and patients with Philadelphia‐like B‐ALL.
Molecular diagnostics of infectious diseases
Procop, Gary W. , Persing, David H., Tang, Yi‐Wei

Mayo Clinic

Clinical Chemistry | January 23, 2020 | Volume: 43 | Issue: 11 | Pages: 2021-2038

10.1093/clinchem/43.11.2021 Get It

Abstract Over the past several years, the development and application of molecular diagnostic techniques has initiated a revolution in the diagnosis and monitoring of infectious diseases. Microbial phenotypic characteristics, such as protein, bacteriophage, and chromatographic profiles, as well as biotyping and susceptibility testing, are used in most routine laboratories for identification and differentiation. Nucleic acid techniques, such as plasmid profiling, various methods for generating restriction fragment length polymorphisms, and the polymerase chain reaction (PCR), are making increasing inroads into clinical laboratories. PCR-based systems to detect the etiologic agents of disease directly from clinical samples, without the need for culture, have been useful in rapid detection of unculturable or fastidious microorganisms. Additionally, sequence analysis of amplified microbial DNA allows for identification and better characterization of the pathogen. Subspecies variation, identified by various techniques, has been shown to be important in the prognosis of certain diseases. Other important advances include the determination of viral load and the direct detection of genes or gene mutations responsible for drug resistance. Increased use of automation and user-friendly software makes these technologies more widely available. In all, the detection of infectious agents at the nucleic acid level represents a true synthesis of clinical chemistry and clinical microbiology techniques.
Molecular evidence and clinical significance of herpesvirus coinfection in the central nervous system
Espy, Mark J., Persing, D. H., Smith, Thomas F., Tang, Yi‐Wei

Mayo Clinic

Journal of Clinical Microbiology | January 6, 2020 | Volume: 35 | Issue: 11 | Pages: 2869-2872

10.1128/jcm.35.11.2869-2872.1997 | PMID 9350749 Get It

A total of 60 cerebrospinal fluid (CSF) specimens from patients manifesting symptoms resembling viral central nervous system (CNS) disease were examined for the presence of herpes simplex virus (HSV), human herpesvirus 6 (HHV-6), Epstein-Barr virus (EBV), cytomegalovirus, varicella-zoster virus, Borrelia burgdorferi, and Tropheryma whippelii DNA by PCR. Of 30 specimens which were selected on the basis of HSV DNA positivity, 2 were concomitantly positive for HHV-6 DNA and 1 was positive for EBV DNA. In the three specimens positive for more than one herpesvirus, amplicons generated with virus-specific primer sets hybridized specifically to the corresponding virus-specific probe. Sequence analysis of the two amplified DNA fragments demonstrated that they were derived from distinct herpesviruses. Of 22 patients with clinically diagnosed encephalitis, 2 of 3 patients coinfected with HSV and HHV-6 died, compared to 1 of 19 (5%) patients infected with only HSV. Of 30 CSF specimens that were negative for HSV DNA, EBV DNA was detected in one sample. These data indicated the presence of DNA specific for two distinct herpesviruses in the same CSF specimen, providing molecular evidence that coinfection with this group of viruses may occur in the CNS.
028 Adherence to the AUA Penile Prosthesis Antibiotic Prophylaxis Guidelines in Diabetic Patients is Associated with Significantly Higher Risks of Device Infection
Towe, Maxwell , Andrianne, Robert, Guise, Amy, Hatzichristodoulou, Georgios , Henry, G.D., Hsieh, Tang‐Hsu , Lentz, A.C., Munarriz, Ricardo , Osmonov, Daniar , Park, S., Perito, Paul , Sadeghi‐Nejad, Hossein , Simhan, Jay , Wang, R., Yafi, Faysal A. , Collaborators, D., Broderick, Gregory A. , Burnett, Arthur L. “Bud” , Gross, Martin , Henry, G.D., Jenkins, Lawrence C. , Lentz, A.C., Park, S Hun

Mayo Clinic

The Journal of Sexual Medicine | January 1, 2020 | Volume: 17 | Issue: Supplement_1 | Pages: S15-S15

10.1016/j.jsxm.2019.11.030 Get It

Identification of Coryneform Bacterial Isolates by Ribosomal DNA Sequence Analysis
Graevenitz, Alexander von, Waddington, Michael, Hopkins, Marlene K., Smith, Douglas H. , Li, Haijing , Kolbert, Christopher P., Montgomery, Stacy O., Persing, David H., Tang, Yi‐Wei

Mayo Clinic

Journal of Clinical Microbiology | December 31, 2019 | Volume: 38 | Issue: 4 | Pages: 1676-1678

10.1128/jcm.38.4.1676-1678.2000 | PMID 10747168 Get It

ABSTRACT Identification of coryneform bacteria to the species level is important in certain circumstances for differentiating contamination and/or colonization from infection, which influences decisions regarding clinical intervention. However, methods currently used in clinical microbiology laboratories for the species identification of coryneform bacteria are often inadequate. We evaluated the MicroSeq 500 16S bacterial sequencing kit (Perkin-Elmer Biosystems, Foster City, Calif.), which is designed to sequence the first 527 bp of the 16S rRNA gene for bacterial identification, by using 52 coryneform gram-positive bacilli from clinical specimens isolated from January through June 1993 at the Mayo Clinic. Compared to conventional and supplemented phenotypic methods, MicroSeq provided concordant results for identification to the genus level for all isolates. At the species level, MicroSeq provided concordant results for 27 of 42 (64.3%) Corynebacterium isolates and 5 of 6 (83.3%) Corynebacterium -related isolates, respectively. Within the Corynebacterium genus, MicroSeq gave identical species-level identifications for the clinically significant Corynebacterium diphtheriae (4 of 4) and Corynebacterium jeikeium (8 of 8), but it identified only 50.0% (15 of 30) of other species ( P < 0.01). Four isolates from the genera Arthrobacter , Brevibacterium , and Microbacterium , which could not be identified to the species level by conventional methods, were assigned a species-level identification by MicroSeq. The total elapsed time for running a MicroSeq identification was 15.5 to 18.5 h. These data demonstrate that the MicroSeq 500 16S bacterial sequencing kit provides a potentially powerful method for the definitive identification of clinical coryneform bacterium isolates.
Comparison of Protein A Gene Sequencing with Pulsed-Field Gel Electrophoresis and Epidemiologic Data for Molecular Typing of Methicillin-Resistant Staphylococcus aureus
Waddington, Michael, Smith, Douglas H. , Manahan, Janice M., Kohner, Peggy C., Highsmith, Leanne M., Li, Haijing , Cockerill, Franklin R., Thompson, Rodney L., Montgomery, Stacy O., Persing, David H., Tang, Yi‐Wei

Mayo Clinic

Journal of Clinical Microbiology | December 31, 2019 | Volume: 38 | Issue: 4 | Pages: 1347-1351

10.1128/jcm.38.4.1347-1351.2000 | PMID 10747105 Get It

ABSTRACT The epidemiologic relatedness of methicillin-resistant Staphylococcus aureus (MRSA) isolates is currently determined by analysis of chromosomal DNA restriction patterns by pulsed-field gel electrophoresis (PFGE). We have evaluated an alternative typing system (MicroSeq StaphTrack Kit; Perkin-Elmer Biosystems) based on the sequence analysis of the chromosomally encoded polymorphic repeat X region of the S. aureus protein A ( spa ) gene. A total of 69 clinical MRSA isolates were divided into 18 groups according to the number and nucleotide sequences of the spa repeats. Molecular typing results obtained both by spa sequencing and from the PFGE patterns were concordant except for one group, which contained 20 isolates recovered over a 2-year period from hospitalized patients at the Mayo Clinic. Although the spa typing patterns were indistinguishable for those isolates, PFGE analysis yielded seven related but distinguishable patterns. Further coagulase gene sequence analysis subtyped those 20 strains into four groups which followed distinct temporal and geographic distributions. During a 2-year epidemic period there were up to 7 fragment changes in PFGE patterns among epidemiologically related isolates, suggesting that PFGE may be unsuitable for long-term typing of strains involved in epidemics. Although more limited than PFGE in discriminatory power, spa sequencing analysis could be used as a screening method for typing of MRSA strains because of the shorter turnaround time, ease of use, and the inherent advantages of sequence analysis, storage, and sharing of information.
Molecular Diagnosis of Herpes Simplex Virus Infections in the Central Nervous System
Mitchell, P. Shawn, Espy, Mark J., Smith, Thomas F., Persing, David H., Tang, Yi‐Wei

Mayo Clinic

Journal of Clinical Microbiology | December 31, 2019 | Volume: 37 | Issue: 7 | Pages: 2127-2136

10.1128/jcm.37.7.2127-2136.1999 | PMID 10364574 Get It